PD09-05 SYSTEMIC INFUSION OF AUTOLOGOUS ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS IN PERITONEAL DIALYSIS PATIENTS: FEASIBILITY AND SAFETY

Field: Medicine (Health Sciences)

You have accessJournal of UrologyStem Cell Research (PD09)1 Apr 2019PD09-05 SYSTEMIC INFUSION OF AUTOLOGOUS ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS IN PERITONEAL DIALYSIS PATIENTS: FEASIBILITY AND SAFETY Sudabeh Alatab, Soroosh Shekarchian, Iraj Njafi, Reza Moghadasali, Mohammad Reza Pourmand, Naser Ahmadbeigi, Tina Bolurieh, Neda Jaroughi, Gholamreza Pourmand*, and Nasser Aghdami Sudabeh AlatabSudabeh Alatab , Soroosh ShekarchianSoroosh Shekarchian , Iraj NjafiIraj Njafi , Reza MoghadasaliReza Moghadasali , Mohammad Reza PourmandMohammad Reza Pourmand , Naser AhmadbeigiNaser Ahmadbeigi , Tina BoluriehTina Bolurieh , Neda JaroughiNeda Jaroughi , Gholamreza Pourmand*Gholamreza Pourmand* , and Nasser AghdamiNasser Aghdami View All Author Informationhttps://doi.org/10.1097/01.JU.0000555263.51262.75AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVES: Using mesenchymal stem cells (MSCs) is regarded as a new therapeutic approach for improving fibrotic diseases. The aim of this study to evaluate the feasibility and safety of systemic infusion of autologous adipose tissue-derived MSCs (AD-MSCs) in peritoneal dialysis (PD) patients with expected peritoneal fibrosis. METHODS: This study was a prospective, open-label, non-randomized, placebo-free, phase I clinical trial. Case group consisted of nine eligible renal failure patients with more than two years of history of being on PD. Autologous AD-MSCs were obtained through lipoaspiration and expanded under good manufacturing practice conditions. Patients received 1.2 ± 0.1—106 cell/kg of AD-MSCs via cubital vein and then were followed for six months at time points of baseline, and then 3 weeks, 6 weeks, 12 weeks, 16 weeks and 24 weeks after infusion. Clinical, biochemical and peritoneal equilibration test (PET) were performed to assess the safety and probable change in peritoneal solute transport parameters. RESULTS: No serious adverse events and no catheter-related complications were found in the participants. 14 minor reported adverse events were self-limited or subsided after supportive treatment. One patient developed an episode of peritonitis and another patient experienced exit site infection, which did not appear to be related to the procedure. A significant decrease in the rate of solute transport across peritoneal membrane was detected by PET (D/P cr=0.77 vs. 0.73, P=0.02). CONCLUSIONS: This study, for the first time, showed the feasibility and safety of AD-MSCs in PD patients and the potentials for positive changes in solute transport. Further studies with larger samples, longer follow-up, and randomized blind control groups to elucidate the most effective route, frequency and dose of MSCs administration, are necessary (Registration Number: IRCT2015052415841N2). Source of Funding: none Tehran; Islamic Republic of Iran© 2019 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 201Issue Supplement 4April 2019Page: e155-e155 Advertisement Copyright & Permissions© 2019 by American Urological Association Education and Research, Inc.MetricsAuthor Information Sudabeh Alatab More articles by this author Soroosh Shekarchian More articles by this author Iraj Njafi More articles by this author Reza Moghadasali More articles by this author Mohammad Reza Pourmand More articles by this author Naser Ahmadbeigi More articles by this author Tina Bolurieh More articles by this author Neda Jaroughi More articles by this author Gholamreza Pourmand* More articles by this author Nasser Aghdami More articles by this author Expand All Advertisement PDF downloadLoading ...